Differences in regulatory T cells (Tregs) in responding and non-responding patients with indolent B-cell or mantle cell lymphoma during treatment with lenalidomide and rituximab ± dexamethasone.
Breakthrough research sheds light on the genetic mutation behind aggressive prostate cancer. Study: CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic ...
Cyclin-dependent kinase 6 (CDK6) plays a crucial role in the G1 phase to S phase transition of the cell cycle. Aberrant activation of CDK6 has been linked with the development and progression of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results